oxaprozin - Profile

What are the generic sources for oxaprozin and what is the scope of patent protection?

Oxaprozin is the generic ingredient in four branded drugs marketed by Solubiomix, Pfizer, Aarxion Anda Hlding, Actavis Elizabeth, Amneal Pharms Co, Chartwell, Dr Reddys Labs Ltd, Ivax Sub Teva Pharms, Mylan Pharms Inc, Pangea, Pharmobedient, Sandoz, Sun Pharm Inds Inc, Teva, and Watson Labs, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for oxaprozin

US Patents:	0
Tradenames:	4
Applicants:	15
NDAs:	16

US Patents and Regulatory Information for oxaprozin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solubiomix	COXANTO	oxaprozin	CAPSULE;ORAL	217927-001	Oct 20, 2023		RX	Yes	Yes
Pfizer	DAYPRO	oxaprozin	TABLET;ORAL	018841-004	Oct 29, 1992	AB	RX	Yes	Yes
Aarxion Anda Hlding	OXAPROZIN	oxaprozin	TABLET;ORAL	075842-001	Apr 12, 2001		DISCN	No	No
Actavis Elizabeth	OXAPROZIN	oxaprozin	TABLET;ORAL	075843-001	Oct 3, 2001		DISCN	No	No

Oxaprozin Investment Scenario and Fundamentals Analysis: Patent/Generic Risk, Revenue Exposure, and Competitive Dynamics

Last updated: July 17, 2026

Oxaprozin is an NSAID marketed in the US primarily for osteoarthritis and rheumatoid arthritis. The investment case hinges on (1) how much of the brand revenue remains versus low-cost generics, (2) whether any dated or still-pending US patents cover key formulations or use-cases, and (3) generic and authorized-competitor supply stability. Because oxaprozin is an older, widely genericized active ingredient, the core downside driver is standard-of-care pricing pressure from multiple ANDA entries and the low marginal value of additional patent layers unless they protect meaningful differentiated products.

What patents protect oxaprozin in the US, and how strong is the patent estate?

Short answer: Oxaprozin’s US IP coverage is typically limited for new entrants because the active ingredient is well past first-sale-era exclusivity. Investable upside in oxaprozin usually comes from late-lived formulation or method-of-use patents tied to specific commercial product labels (dose forms, release characteristics, or use timing) rather than from active-ingredient process or broad pharmacology claims.

Where patent protection usually exists for oxaprozin-based products

For older NSAIDs like oxaprozin, the enforceable estate (if any) most often concentrates in:

• Formulation patents: specific excipient systems, coating architectures, or release profiles that map to marketed dosage forms.
• Method-of-use patents: narrower patient subpopulations or treatment regimens aligned with label language.
• Manufacturing method patents: process controls that create patentable intermediates or validated manufacturing steps.

How to pressure-test patent strength for an investment

From an investment lens, patent “strength” for oxaprozin should be assessed through:

• Orange Book coverage specificity: whether listed patents are tied to a specific NDA/strength/dosage form rather than broad “umbrella” claims.
• Age and prosecution posture: how close listed patents are to expiration and whether they appear to be late-stage continuation claims.
• Litigation history: whether patent owners have previously enforced the estate via injunction threats or licensing.

When does oxaprozin lose exclusivity, and what are the key expiration timelines?

Short answer: Oxaprozin’s practical exclusivity window has largely elapsed for the active ingredient. The remaining exclusivity question for investors is whether any still-listed US patents protect specific product configurations still generating nontrivial brand or higher-margin revenue.

Exclusivity vs patents: what matters commercially

• US patent expiration controls the ability to launch non-infringing ANDAs.
• Regulatory exclusivities (if any) are tied to exclusivity grants (not common for many older NSAIDs).
• Commercial reality is driven by the number of ANDA suppliers, discounting intensity, and pharmacy channel switching.

Timeline framework investors should use

• Near-term (0 to 18 months): identify pending ANDA approvals and any recent Paragraph IV activity.
• Mid-term (18 to 48 months): map patent expirations by dosage form/strength to forecast incremental competitive intensity.
• Out-late (48+ months): assess whether any “secondary” patents (formulation or method-of-use) remain enforceable and whether settlements create delayed entry.

What generic entry risks exist for oxaprozin, including Paragraph IV challenges?

Short answer: Generic entry risk for oxaprozin is typically dominated by already-mature ANDA competition. New risk emerges mainly if a “secondary” patent is newly enforced or a settlement delays entry for only part of the product catalog.

How Paragraph IV challenges change the investment case

Paragraph IV value is less about litigation duration and more about:

• whether the FDA approval date for an ANDA is delayed due to litigation,
• whether settlements create predictable launch timing for multiple competitors,
• whether the market receives a supply shock or price drop on launch.

Generic scenario matrix investors use

• Scenario A (low incremental risk): most ANDAs already launched; remaining patents are weak or not tied to significant volume.
• Scenario B (moderate risk): one or two dosage strengths have still-protected IP; generic launches could be delayed or staggered.
• Scenario C (high risk): a meaningful brand remnant depends on a still-listed formulation/method patent; an ANDA settlement can trigger a sharp volume shift once protected coverage falls.

What is the Orange Book status of oxaprozin, and how many patents cover the marketed product?

Short answer: The Orange Book is the correct structure to quantify remaining US patent coverage by NDA, dosage form, strength, and each listed patent’s expiration. The investment conclusion is driven by whether:

• listed patents remain in force for high-volume presentations, and
• those patents have enforceability through prior litigation or credible injunction posture.

How to interpret Orange Book listings for an investment decision

Key metrics:

• Patent count by dosage form: high counts can signal either dense protection or low-priority, quickly invalidated claim families.
• Remaining term: patents with long remaining terms can still be commercially irrelevant if they do not map to the primary product NDCs used in substitution.
• CPCs and claim types: formulation patents with narrow, product-specific claim language create higher launch barriers than broad method claims.

What formulations and dosage forms of oxaprozin are patented or contested?

Short answer: For oxaprozin, the main differentiation for IP and generic barriers typically lies in the tablet formulation rather than injectable or biologic platforms. Investors should focus on:

• excipient systems,
• tablet coating and dissolution profile,
• any delayed-release or controlled-release features (if present by label or marketed product).

Where formulation patents drive value

Formulation IP can matter even when active-ingredient patents are dead if:

• generic manufacturers need non-trivial composition changes,
• dissolution testing thresholds map to claim limitations,
• the brand has designed a proprietary release profile aligned with clinician dosing behavior.

What method-of-use patents cover oxaprozin, and do they impact generic launch more than formulation patents?

Short answer: Method-of-use patents can block launch if they are listed for the relevant NDA and the carve-out strategy does not avoid infringement. For older NSAIDs, method-of-use coverage is often narrow and label-dependent, which reduces its generic-blocking power unless it is tightly connected to the predominant marketed indications.

Investment impact: label carve-outs and “skinny labeling”

• If a method-of-use patent is enforceable only for a specific indication subpopulation, generic sponsors can often pursue label carve-outs or a “skinny label” strategy.
• If the method-of-use claim aligns exactly with the primary label, the blocking effect is higher.

Which companies manufacture oxaprozin in the US, and how does the competitive landscape affect revenue?

Short answer: Oxaprozin competition is driven by multiple generic manufacturers and pharmacy substitution dynamics. Revenue durability is mostly a function of:

• whether any brand remnant survives through payer contracts,
• whether certain strengths or NDCs have fewer qualified suppliers,
• whether supply-chain disruptions affect price elasticity.

Competitive dynamics investors should track

• Qualified generic launches: number of ANDA approvals per strength and the timeline clustering.
• Price dispersion: shrinkage of net price as additional entrants arrive.
• Inventory and supply: if production capacity is constrained for certain tablet strengths, price can remain higher even post-patent.

What oxaprozin litigation affects investors, including settlements and injunctions?

Short answer: Oxaprozin’s litigation profile is typically less “headline” than biologics or oncology, but still matters if any enforceable formulation/use patent remains on the Orange Book for the volumes that still exist.

What to extract from litigation records

Investment-grade litigation analysis should capture:

• filing and service dates for each case,
• whether motions led to stay or expediting schedules,
• whether settlements specify launch dates, labeling limits, or design-around constraints,
• whether injunctions were sought for specific NDCs.

What is the FDA regulatory status of oxaprozin, including ANDA approvals and labeling changes?

Short answer: Oxaprozin is approved for chronic use conditions commonly aligned with osteoarthritis and rheumatoid arthritis. In an investment context, the FDA lens is:

• which ANDAs are approved by strength and dosage form,
• whether labeling has shifted through safety updates (NSAID class label),
• whether any REMS or risk communications changed market behavior.

How regulatory status feeds into revenue modeling

• More ANDA approvals lead to substitution acceleration.
• Safety communications can affect utilization rates more than IP once generic supply is stable.

How does oxaprozin compare with other NSAIDs for investment risk and market stability?

Short answer: Compared with newer, protected NSAID platforms, oxaprozin has higher exposure to generic price compression. Compared with other older generics, its risk profile depends on tablet-specific differentiation that can occasionally preserve pricing in certain channel pockets.

Relative investment factors

• Moat depth: usually shallow versus proprietary brands.
• Switching resistance: low due to therapeutic interchangeability among NSAIDs.
• Volume exposure: sensitive to formularies, payer step edits, and copay design.

What generic launch scenarios exist for oxaprozin, and what would be the expected revenue impact?

Short answer: The most likely launch scenario is incremental supply expansion in already genericized categories. Revenue risk is therefore less about “first generic entry” and more about “additional entry and price erosion,” with potentially faster declines for under-supplied strengths.

Launch scenario map investors should model

• Strength-level surge: one strength gains multiple new ANDAs; price drops faster than volume grows.
• Staggered entry: fewer entrants per quarter; net price declines are more gradual.
• Supply constraint reversal: manufacturing downtime ends; price returns toward generic floor.

What manufacturing and IP barriers could slow generic competition for oxaprozin tablets?

Short answer: For tablet NSAIDs, the main barriers are practical:

• ability to match dissolution and stability specs,
• regulatory quality history,
• any remaining proprietary formulation constraints tied to patent claims.

Barriers that affect margin sustainability

• Higher manufacturing defect rates raise recall risk and slow approvals.
• Bioequivalence and dissolution test failures can delay competitive launches.

Key Takeaways

• Oxaprozin’s investment case is predominantly a late-cycle generic market story: net price and competitive intensity dominate over patent-driven upside.
• The only defensible upside usually comes from still-in-force, Orange-Book-listed secondary patents tied to specific dosage forms or narrow method-of-use claims.
• The highest near-to-mid term risk is incremental ANDA entry and price compression, especially at the strength/NDC level.
• Litigation and settlements matter less as events and more as predictors of launch timing and whether label carve-outs reduce the blocking effect.

FAQs

1. How do Orange Book-listed oxaprozin patents map to specific NDCs and strengths?
2. Does oxaprozin method-of-use IP block generics if a skinny-label carve-out is available?
3. What indicators best predict an oxaprozin price drop after new ANDA approvals?
4. How do NSAID class label updates typically affect utilization for oxaprozin versus alternative NSAIDs?
5. What strength-level supply constraints most often preserve generic pricing for older tablet NSAIDs like oxaprozin?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-17).